Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study

about

Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study

Item

http://www.wikidata.org/entity/Q58608206

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Clinical Validation of Newly D ...... Results of the RASKET-B Study

@en

Clinical Validation of Newly D ...... Results of the RASKET-B Study

@nl

type

Item

label

Clinical Validation of Newly D ...... Results of the RASKET-B Study

@en

Clinical Validation of Newly D ...... Results of the RASKET-B Study

@nl

prefLabel

Clinical Validation of Newly D ...... Results of the RASKET-B Study

@en

Clinical Validation of Newly D ...... Results of the RASKET-B Study

@nl

P1476

Clinical Validation of Newly D ...... Results of the RASKET-B Study

@en

P2093

Hiroki Hara

http://www.w3.org/2001/XMLSchema#string

Hiroya Taniguchi

http://www.w3.org/2001/XMLSchema#string

Kei Muro

http://www.w3.org/2001/XMLSchema#string

Kiwamu Akagi

http://www.w3.org/2001/XMLSchema#string

Shuichi Hironaka

http://www.w3.org/2001/XMLSchema#string

Tadamichi Denda

http://www.w3.org/2001/XMLSchema#string

Takayuki Yoshino

http://www.w3.org/2001/XMLSchema#string

Takeharu Yamanaka

http://www.w3.org/2001/XMLSchema#string

Takeshi Kajiwara

http://www.w3.org/2001/XMLSchema#string

Taroh Satoh

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Mutations of the BRAF gene in human cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population.

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147

P304

1219-1226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEO.2018.10.004

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30412858

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

cancer research

P932

6226617

http://www.w3.org/2001/XMLSchema#string